Merck completes acquisition of Verona Pharma; VRNA shares delisted from Nasdaq
PositiveFinancial Markets

Merck has successfully completed its acquisition of Verona Pharma, leading to the delisting of VRNA shares from Nasdaq. This move is significant as it highlights Merck's commitment to expanding its portfolio in the pharmaceutical sector, particularly in respiratory diseases. The acquisition is expected to enhance Merck's research capabilities and market presence, ultimately benefiting patients and investors alike.
— Curated by the World Pulse Now AI Editorial System